Aleafia Labs Partners on Cannabinoid Pharmacogenetics Study

This information was provided by aleafiainc.com

Send your Press Release here.

Aleafia Labs Partners on Cannabinoid Pharmacogenetics Study
Study with G420, US-Based AKESOgen aimed at producing genetic tools for improved medical cannabis therapy 

TORONTO, October 30, 2018 /Globe Newswire/ – Aleafia Labs, a division of Aleafia Health Inc. (TSXV: ALEF: OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) and Guided 420 Genetics Inc. (“G420”) with U.S.-based AKESOgen, Inc., (“AKESOgen”), together the (“Parties”), are announcing the commencement of a joint study (“the Study”) on cannabinoid pharmacogenetics in medical cannabis therapy. The initial 200 patient study will focus on developing medical cannabis patient genetic screening tools in the areas of THC-CBD sensitivity and metabolism, Endocannabinoid Deficiency Syndrome and cannabis treatment safety and adverse event risk.

This initiative will be funded by G420 and will be administered by Aleafia physicians practicing within the Canabo Medical Clinic network. The Study is expected to generate unique intellectual property assets that can be used towards proprietary product development and tools to improve medical cannabis treatment of major illnesses. It is expected that this study will lead to additional clinical investigations and larger retrospective cohort studies as well as prospective clinical trials based on the indications generated.

“Aleafia is pleased to partner with G420/AKESOgen in a first of its kind cannabis related pharmacogenomics study,” said Aleafia President of Clinic Operations, Dr. Gary Goodyear. “Aleafia’s unique medical cannabis clinic business perfectly complements a robust clinical research strategy that should yield benefits to patients through the form of improved treatment methods and product development.”

“Utilizing pharmacogenetics to better manage safety and efficacy for the administration of medical cannabis in a precise manner is a large unmet need in a fast-growing industry,” added Dr. Mark Bouzyk, AKESOgen’s Chief Scientific Officer. “The combination of G420/AKESOgen’s resources and expertise in genetic analysis and genomic study management combined with Aleafia’s leading clinical footprint in Canada’s medical cannabis sector has very exciting potential for new knowledge and therapy applications in this rapidly developing field.”

“Effective genetic screening tools have the potential to dramatically improve patient outcomes through more accurate dosing and treatment targeting,” said Aleafia Chief Medical Officer Dr. Michael Verbora. “This includes application in opioid replacement therapy and chronic illness treatment such as those currently used for cancer.”

Emerald contributor since March 2012

Comments

Your email address will not be published.